Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tyrosinaemia type I--an update.

E A Kvittingen1

  • 1Institute of Clinical Biochemistry, Rikshospitalet, Oslo, Norway.

Journal of Inherited Metabolic Disease
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Tyrosinaemia type I, a genetic disorder, stems from fumarylacetoacetase (FAH) deficiency. Early diagnosis via succinylacetone (SA) levels and FAH enzyme assays is crucial for managing liver and kidney complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.

HIV medicine·2005
Same author

Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.

Journal of molecular medicine (Berlin, Germany)·2005
Same author

Acute respiratory distress syndrome in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies.

Journal of inherited metabolic disease·2003
Same author

Two novel aspartoacylase gene (ASPA) missense mutations specific to Norwegian and Swedish patients with Canavan disease.

Journal of medical genetics·2002
Same author

Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome.

Cancer detection and prevention·2000
Same author

Evidence that Alpers-Huttenlocher syndrome could be a mitochondrial disease.

Journal of child neurology·2000

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Tyrosinaemia type I is an inherited metabolic disorder due to fumarylacetoacetase (FAH) deficiency.
  • Accumulation of toxic metabolites like succinylacetone (SA) leads to severe liver and kidney damage.
  • Hepatocellular carcinoma is a significant cause of mortality in chronic cases.

Purpose of the Study:

  • To outline the pathophysiology and clinical manifestations of Tyrosinaemia type I.
  • To detail diagnostic methods for Tyrosinaemia type I, including prenatal diagnosis.
  • To discuss current treatment options and long-term outcomes.

Main Methods:

  • Biochemical assays for succinylacetone (SA) in urine and serum.
  • Enzyme activity determination of fumarylacetoacetase (FAH) in patient cells.

Related Experiment Videos

  • Genetic analysis using FAH cDNA probes and polymorphism studies.
  • Immunoblot analysis for FAH protein detection.

    • Main Results:

    • Increased SA levels and deficient FAH enzyme activity confirm the diagnosis.
    • Prenatal diagnosis is feasible but complicated by FAH pseudodeficiency alleles.
    • FAH protein is absent in acute and some chronic patients.
    • FAH gene mapped to chromosome 15q23-q25.

    Conclusions:

    • Accurate diagnosis of Tyrosinaemia type I relies on biochemical and genetic testing.
    • Liver transplantation is the definitive treatment, but renal complications may persist.
    • Ongoing research into FAH gene polymorphisms aids complex prenatal diagnoses.